Immunohistochemical evaluation of vasopressin expression in breast fibrocystic disease and ductal carcinoma in situ (DCIS)

Endocr Pathol. 2003 Fall;14(3):257-62. doi: 10.1007/s12022-003-0018-y.

Abstract

We previously found that expression of the vasopressin gene is a common feature of human breast cancer. In the present study we first examined 21 different cases of benign fibrocystic breast disease for vasopressin expression using immunohistochemistry and antibodies directed against vasopressin (anti-VP) and against vasopressin-associated glycopeptide (anti-VAG). All cases examined were negative for vasopressin gene expression using these antibodies. Alternatively, we examined 16 cases of breast ductal carcinoma in situ (DCIS) using the second of these antibodies (anti-VAG), and all of these cases were positive for vasopressin gene expression. Our results suggest that products of vasopressin gene expression are not markers of cellular proliferation in the breast, and might rather represent an early part of the carcinogenic process in this tissue.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Biopsy
  • Breast Neoplasms / genetics
  • Breast Neoplasms / pathology*
  • Carcinoma, Ductal / genetics
  • Carcinoma, Ductal / pathology*
  • Female
  • Fibrocystic Breast Disease / genetics
  • Fibrocystic Breast Disease / pathology*
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Immunohistochemistry
  • Retrospective Studies
  • Vasopressins / analysis
  • Vasopressins / genetics*

Substances

  • Vasopressins